Last reviewed · How we verify
GSK investigational vaccine GSK2340269A
GSK investigational vaccine GSK2340269A is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Investigational indication under Phase 3 evaluation (specific indication not publicly confirmed).
GSK2340269A is an investigational vaccine designed to stimulate immune responses against specific tumor-associated antigens or infectious disease targets.
GSK2340269A is an investigational vaccine designed to stimulate immune responses against specific tumor-associated antigens or infectious disease targets. Used for Investigational indication under Phase 3 evaluation (specific indication not publicly confirmed).
At a glance
| Generic name | GSK investigational vaccine GSK2340269A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology/Oncology |
| Phase | Phase 3 |
Mechanism of action
As a vaccine candidate in development by GlaxoSmithKline, GSK2340269A likely works by priming the adaptive immune system to recognize and attack cells expressing particular antigens. The exact antigenic target and immunological approach (e.g., viral vector, protein subunit, nucleic acid platform) are not publicly detailed in widely available sources, limiting specificity of the mechanism description.
Approved indications
- Investigational indication under Phase 3 evaluation (specific indication not publicly confirmed)
Common side effects
Key clinical trials
- Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE3)
- Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK investigational vaccine GSK2340269A CI brief — competitive landscape report
- GSK investigational vaccine GSK2340269A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK investigational vaccine GSK2340269A
What is GSK investigational vaccine GSK2340269A?
How does GSK investigational vaccine GSK2340269A work?
What is GSK investigational vaccine GSK2340269A used for?
Who makes GSK investigational vaccine GSK2340269A?
What drug class is GSK investigational vaccine GSK2340269A in?
What development phase is GSK investigational vaccine GSK2340269A in?
Related
- Drug class: All Vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology/Oncology
- Indication: Drugs for Investigational indication under Phase 3 evaluation (specific indication not publicly confirmed)
- Compare: GSK investigational vaccine GSK2340269A vs similar drugs
- Pricing: GSK investigational vaccine GSK2340269A cost, discount & access